Research Reports Coverage on Biotech Stocks -- Achaogen, Bellicum Pharma, Coherus BioSciences, and Conatus Pharma

Thursday, June 1, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 1, 2017 /PRNewswire/ --

On Wednesday, the NASDAQ Composite ended the day at 6,198.52, down 0.08%;

the Dow Jones Industrial Average edged 0.10% lower, to finish at 21,008.65; and the S&P 500 closed at 2,411.80, slightly slipping 0.05%. Gains were broad based as five out of nine sectors finished the trading session in green. has
initiated research reports on the following Biotechnology stocks: Achaogen Inc. (NASDAQ: AKAO), Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM), Coherus BioSciences Inc. (NASDAQ: CHRS), and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). Learn more about these stocks by downloading their comprehensive and free reports at:


South San Francisco, California-based Achaogen Inc.'s stock finished Wednesday's session 0.30% lower at $20.18. A total volume of 1.37 million shares was traded, which was above their three months average volume of 902,530 shares. The Company's shares have advanced 54.99% since the start of this year. The stock is trading 45.08% above its 200-day moving average. Additionally, shares of Achaogen, which discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the US, have a Relative Strength Index (RSI) of 35.07.

On May 09th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $28 a share to $31 a share. AKAO complete research report is just a click away and free at:

Bellicum Pharma  

On Wednesday, shares in Houston, Texas headquartered Bellicum Pharmaceuticals Inc. recorded a trading volume of 817,611 shares, which was above their three months average volume of 646,890 shares. The stock ended the session 6.61% lower at $10.59. The Company's shares are trading 17.92% below their 50-day moving average. Moreover, shares of Bellicum Pharma, which focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the US and internationally, have an RSI of 29.24. The complimentary report on BLCM can be downloaded at:

Coherus BioSciences  

Redwood City, California headquartered Coherus BioSciences Inc.'s shares closed the day 4.82% lower at $19.75. The stock recorded a trading volume of 429,525 shares. The Company's shares are trading 3.96% below their 50-day moving average. Additionally, shares of Coherus BioSciences, which focuses on developing and commercializing biosimilar products worldwide, have an RSI of 43.22.

On May 05th, 2017, research firm BMO Capital Markets initiated an 'Outperform' rating on the Company's stock, with a target price of $54 per share. Sign up for your complimentary research report on CHRS at:

Conatus Pharma  

Shares in San Diego, California headquartered Conatus Pharmaceuticals Inc. finished 0.20% lower at $4.93. The stock recorded a trading volume of 609,200 shares. The Company's shares have advanced 1.65% in the previous three months. The stock is trading above its 200-day moving average by 27.44%. Furthermore, shares of Conatus Pharma, which focuses on the development and commercialization of novel medicines to treat liver diseases in the US, have an RSI of 33.49. Get free access to your research report on CNAT at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store